MX2016013741A - Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. - Google Patents
Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.Info
- Publication number
- MX2016013741A MX2016013741A MX2016013741A MX2016013741A MX2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A
- Authority
- MX
- Mexico
- Prior art keywords
- parkinson
- patient
- disease
- rapid relief
- motor fluctuations
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 3
- 206010030312 On and off phenomenon Diseases 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona métodos para el tratamiento períodos INACTIVOS en pacientes con la Enfermedad de Parkinson que comprenden la administración de levopoda en el sistema pulmonar de un paciente en donde posterior a la administración, mejora la puntuación de la Escala de Evaluación Unificada de la Enfermedad Parkinson (UPDRS) Parte 3 del paciente, por ejemplo, por al menos unos 5 puntos en comparación con el placebo control y/o en comparación con la puntuación de UPDRS III del paciente previo a la administración. La invención también proporciona métodos de reducción del promedio diaria de tiempo INACTIVO en un paciente con Parkinson.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/034778 WO2015163840A1 (en) | 2014-04-21 | 2014-04-21 | Rapid relief of motor fluctuations in parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016013741A true MX2016013741A (es) | 2017-04-06 |
Family
ID=54332876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013741A MX2016013741A (es) | 2014-04-21 | 2014-04-21 | Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20170296498A1 (es) |
| EP (2) | EP3831375A1 (es) |
| JP (1) | JP2017513866A (es) |
| KR (2) | KR20170008754A (es) |
| CN (2) | CN113209055A (es) |
| AU (2) | AU2014391721B2 (es) |
| BR (1) | BR112016024502A8 (es) |
| CA (1) | CA2946165C (es) |
| IL (2) | IL309959A (es) |
| MX (1) | MX2016013741A (es) |
| RU (1) | RU2698330C2 (es) |
| SG (1) | SG11201608608PA (es) |
| WO (1) | WO2015163840A1 (es) |
| ZA (1) | ZA201607833B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014074797A1 (en) | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| AU2019205327A1 (en) * | 2018-01-05 | 2020-07-30 | Impel Pharmaceuticals Inc. | Intranasal delivery of levodopa powder by precision olfactory device |
| CN112955134A (zh) | 2018-07-19 | 2021-06-11 | 英倍尔药业股份有限公司 | 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| WO2003079992A2 (en) | 2002-03-20 | 2003-10-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery for levodopa |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US8496002B2 (en) | 2007-06-12 | 2013-07-30 | Civitas Therapeutics, Inc. | Powder inhaler devices |
| GB2454480A (en) * | 2007-11-07 | 2009-05-13 | Vectura Group Plc | Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders |
| MX2010014222A (es) * | 2008-06-30 | 2011-03-29 | Novartis Ag Star | Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson. |
| US8399513B2 (en) * | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| TW201304822A (zh) * | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
| MX2021014782A (es) * | 2012-10-22 | 2023-03-23 | Civitas Therapeutics Inc | Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson. |
| US8545878B1 (en) * | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
-
2014
- 2014-04-21 US US15/500,608 patent/US20170296498A1/en not_active Abandoned
- 2014-04-21 CN CN202110185196.6A patent/CN113209055A/zh active Pending
- 2014-04-21 IL IL309959A patent/IL309959A/en unknown
- 2014-04-21 KR KR1020167032453A patent/KR20170008754A/ko active Application Filing
- 2014-04-21 CN CN201480079968.6A patent/CN106659685B/zh active Active
- 2014-04-21 CA CA2946165A patent/CA2946165C/en active Active
- 2014-04-21 JP JP2016563193A patent/JP2017513866A/ja active Pending
- 2014-04-21 RU RU2016144340A patent/RU2698330C2/ru active
- 2014-04-21 EP EP21150770.2A patent/EP3831375A1/en active Pending
- 2014-04-21 MX MX2016013741A patent/MX2016013741A/es unknown
- 2014-04-21 SG SG11201608608PA patent/SG11201608608PA/en unknown
- 2014-04-21 KR KR1020217038097A patent/KR20210144946A/ko not_active IP Right Cessation
- 2014-04-21 WO PCT/US2014/034778 patent/WO2015163840A1/en active Application Filing
- 2014-04-21 AU AU2014391721A patent/AU2014391721B2/en active Active
- 2014-04-21 BR BR112016024502A patent/BR112016024502A8/pt not_active Application Discontinuation
- 2014-04-21 EP EP14889874.5A patent/EP3134077A4/en not_active Ceased
-
2016
- 2016-10-20 IL IL248445A patent/IL248445A0/en unknown
- 2016-11-14 ZA ZA2016/07833A patent/ZA201607833B/en unknown
-
2020
- 2020-09-24 AU AU2020239754A patent/AU2020239754B2/en active Active
-
2022
- 2022-01-26 US US17/584,663 patent/US20230053976A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016144340A3 (es) | 2018-05-22 |
| EP3134077A1 (en) | 2017-03-01 |
| RU2698330C2 (ru) | 2019-08-26 |
| KR20170008754A (ko) | 2017-01-24 |
| CN106659685B (zh) | 2021-02-05 |
| IL309959A (en) | 2024-03-01 |
| CA2946165A1 (en) | 2015-10-29 |
| KR20210144946A (ko) | 2021-11-30 |
| JP2017513866A (ja) | 2017-06-01 |
| CN113209055A (zh) | 2021-08-06 |
| WO2015163840A1 (en) | 2015-10-29 |
| CN106659685A (zh) | 2017-05-10 |
| ZA201607833B (en) | 2018-08-29 |
| EP3831375A1 (en) | 2021-06-09 |
| EP3134077A4 (en) | 2017-12-20 |
| US20170296498A1 (en) | 2017-10-19 |
| IL248445A0 (en) | 2016-12-29 |
| SG11201608608PA (en) | 2016-11-29 |
| US20230053976A1 (en) | 2023-02-23 |
| RU2016144340A (ru) | 2018-05-22 |
| AU2020239754B2 (en) | 2022-06-23 |
| BR112016024502A8 (pt) | 2021-06-29 |
| BR112016024502A2 (pt) | 2017-08-15 |
| AU2014391721B2 (en) | 2020-07-16 |
| AU2020239754A1 (en) | 2021-01-14 |
| AU2014391721A1 (en) | 2016-11-03 |
| CA2946165C (en) | 2022-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| SA521421115B1 (ar) | عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام | |
| MX2015015249A (es) | Peptidos terapeuticos. | |
| MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| MX351508B (es) | Sistemas y métodos para el diseño y fabricación de calzado de protección de pacientes. | |
| TW201613636A (en) | Methods of treating Alzheimer's Disease | |
| PH12018501072A1 (en) | Modified release orally administered amino acid formulations | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
| EA201992832A1 (ru) | Подкожное введение adamts13 | |
| MX2019003710A (es) | Compuestos y metodos de p2x3 y/o p2x2/3. | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| MX2016013741A (es) | Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. | |
| PH12017501304A1 (en) | Levodopa and carbidopa intestinal gel and method of use | |
| WO2014111790A3 (en) | Stable transdermal pharmaceutical drug delivery system comprising rivastigmine | |
| MX2019000677A (es) | Células miméticas de células b. | |
| MX2018005028A (es) | Composicion para el cuidado de la piel y metodos para la misma. | |
| MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
| WO2018026776A3 (en) | Foxm1 modulators and uses thereof | |
| WO2014006571A3 (en) | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof | |
| TR201903234T4 (tr) | Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. | |
| SG11201903834XA (en) | Medical skin external preparation | |
| WO2014155268A3 (en) | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |